差别PCR技术检测乳腺癌c-erbB-2癌基因扩增的研究  

The Study on the Detection of c-erbB-2 Oncogene in Breast Cancer Amplification with Differential Polymerase Chain Reaction

作　　者：苏丽娅[1] 曹虹然[2] 白雪峰[2] 秦文斌[1] 岳秀兰[1] 

机构地区：[1]包头医学院生物化学与分子生物学教研室,内蒙古包头014010 [2]包头市第七医院病理科

出　　处：《包头医学院学报》2006年第2期119-121,共3页Journal of Baotou Medical College

基　　金：内蒙古自然科学基金;批准号200308020611

摘　　要：目的:探讨乳腺癌c-erbB-2癌基因扩增的临床意义。方法:应用差别PCR技术检测50例原发性乳腺癌c-erbB-2癌基因的扩增情况。结果:乳腺癌组织中c-erbB-2癌基因的扩增率为44·0%(22/50),33例有腋淋巴结转移者乳腺癌组织c-erbB-2阳性表达率(54.5%)高于17例无腋淋巴结转移者(23.5%),乳腺癌组织中c-erbB-2癌基因扩增与患者年龄、肿块大小、分化程度、病理类型、ER及PR无显著相关性。结论:c-erbB-2癌基因扩增对乳腺癌的治疗、预后判断具有重要的临床应用意义。Objective：To explore the clinical significance of e-erbB-2 oncogene amplification in breast cancer. Methods： c-erbB-2 oncogene amplification was examined by using differential polymerase chain reation in 50 cases of breast cancer. Results c-erbB-2 oncogene ampification was found in 44. 0% （22/50） of breast cancer patients ,the positive expression rate of c-erbB-2 was 54.5% in 33 cases of breast cancer with axillary lymph node metastasis and 23.5% in 17 cases of breast cancer without metastasis（P 〈0.05）, c-erbB-2 oncogene amplification was not correlated to age, tumor size and histologic grade pathotogical types. Conclusion： The results suggest that c-erbB-2 amplification plays a role in the treatment of breast cancer and may be one of those significant prognostic factors for therapy ,predicting prognosis for breast cancer.

关 键 词：乳腺癌 C-ERBB-2 差别PCR 癌基因扩增 

分 类 号：R737.9[医药卫生—肿瘤]